Gaudium IVF Q3 FY26 Net Profit at ₹3.63 Crore, Revenue at ₹24.51 Crore
Gaudium IVF reported Q3 FY26 unaudited results with net profit at ₹3.63 crore and revenue at ₹24.51 crore. For 9M FY26, net profit was ₹16.15 crore on revenue of ₹74.01 crore. The company successfully completed its IPO, raising ₹165.00 crore and listing on exchanges on February 27, 2026.
The financial results are positive, and the recent IPO and listing are significant corporate actions that will impact the company's growth and market presence. However, the impact is considered medium as the financial figures are for a past quarter and not a forward-looking guidance.
The company reported positive financial results for the quarter and nine months ended December 31, 2025, and highlighted the successful completion of its IPO and listing, indicating a strong growth phase.
Gaudium IVF and Women Health Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a net profit of ₹363.05 lakh (₹3.63 crore) for the third quarter of FY26, with revenue from operations at ₹2,450.70 lakh (₹24.51 crore). Total income for the quarter stood at ₹2,461.00 lakh (₹24.61 crore), and profit before tax (PBT) was ₹496.31 lakh (₹4.96 crore).
For the nine months ended December 31, 2025, revenue from operations reached ₹7,400.58 lakh (₹74.01 crore), with total income at ₹7,435.97 lakh (₹74.36 crore). The PBT for the nine-month period was ₹2,174.59 lakh (₹21.75 crore), and the net profit was ₹1,614.90 lakh (₹16.15 crore).
The company highlighted its successful Initial Public Offering (IPO), which raised approximately ₹16,500.098 lakh (₹165.00 crore) and was followed by its listing on the National Stock Exchange of India Limited and BSE Limited on February 27, 2026.
Dr. Manika Khanna, Chairperson and Managing Director, commented, "This is not just a quarter of strong performance, it reflects a category that is coming of age, and Gaudium IVF is at the forefront of shaping it. Our listing marks a structural shift, from building a trusted clinical brand to institutionalising a scalable, future-ready healthcare platform. We have been deliberate in how we grow, combining clinical excellence with operational discipline. The opportunity in fertility care in India is significantly underpenetrated, and we see ourselves not just participating in this growth but leading it. Our focus is clear, expand access, deepen outcomes, and build India’s most trusted and outcome-driven fertility network."
What to do with a filing like this
Gaudium IVF and Women Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gaudium IVF and Women Health Limited. Read the original for the full detail.